anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An implantable ocular drain includes a body and a compliant portion. The body includes a first end configured to seat in an anterior chamber of an eye. The first end includes an inlet for ingress of aqueous humor into the implantable ocular drain. The body further includes a second end configured to seat in a tear film of the eye. The second end includes an outlet to release a flow of the aqueous humor into the tear film. The body further defines a tortuosity and a fluid conduit. The body includes a lumen having a lumen length and a lumen cross sectional area. The lumen length and the lumen cross sectional area and the tortuosity are configured to control an intraocular pressure (IOP) of the eye by controlling the flow of the aqueous humor through the lumen. The compliant portion is at the second end.
Cognitive impairment (CI) is a complication of chronic kidney disease (CKD) that is frequently observed among patients. The aim of this study was to evaluate the potential crosstalk between changes in cognitive function and the levels of Klotho in the brain cortex in an experimental model of CKD. To induce renal damage, Wistar rats received a diet containing 0.25% adenine for six weeks, while the control group was fed a standard diet. The animals underwent different tests for the assessment of cognitive function. At sacrifice, changes in the parameters of mineral metabolism and the expression of Klotho in the kidney and frontal cortex were evaluated. The animals with CKD exhibited impaired behavior in the cognitive tests in comparison with the rats with normal renal function. At sacrifice, CKD-associated mineral disorder was confirmed by the presence of the expected disturbances in the plasma phosphorus, PTH, and both intact and c-terminal FGF23, along with a reduced abundance of renal Klotho. Interestingly, a marked and significant decrease in Klotho was observed in the cerebral cortex of the animals with renal dysfunction. In sum, the loss in cerebral Klotho observed in experimental CKD may contribute to the cognitive dysfunction frequently observed among patients. Although further studies are required, Klotho might have a relevant role in the development of CKD-associated CI and represent a potential target in the management of this complication.
The cardiovascular complications of atherosclerosis are thought to arise from an inflammatory response to the accumulation of cholesterol-rich lipoproteins in the arterial wall. The positive outcome of CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) provided key evidence to support this concept and suggested that inflammasomes and IL-1β are important inflammatory mediators in human atherosclerotic cardiovascular diseases (ACVD). In specific settings NLRP3 or AIM2 inflammasomes can induce inflammatory responses in the arterial wall and promote the formation of unstable atherosclerotic plaques. Clonal hematopoiesis (CH) has recently emerged as a major independent risk factor for ACVD. CH mutations arise during ageing and commonly involves variants in genes mediating epigenetic modifications (TET2, DNMT3A, ASXL1) or cytokine signaling (JAK2). Accumulating evidence points to the role of inflammasomes in the progression of CH-induced ACVD events and has shed light on the regulatory pathways and possible therapeutic approaches that specifically target inflammasomes in atherosclerosis. Epigenetic dynamics play a vital role in regulating the generation and activation of inflammasome components by causing changes in DNA methylation patterns and chromatin assembly. This review examines the genetic and epigenetic regulation of inflammasomes, the intersection of macrophage cholesterol accumulation with inflammasome activation and their roles in atherosclerosis. Understanding the involvement of inflammasomes in atherosclerosis pathogenesis may lead to customized treatments that reduce the burden of ACVD.
The study is a Phase 1/2a, multicenter, randomized (the study medication is assigned by chance), single dose, dose escalation, fellow-eye controlled study evaluating the safety and clinical response of a single, subretinal administration of CNTO 2476 in patients with visual acuity impairment associated with GA secondary to AMD. The study will consist of screening (up to 21 days prior to treatment) period, treatment (Day 1) period and follow up period. The study will be conducted in 2 portions: the Phase 1 portion will include dose escalation and the Phase 2 portion will enroll additional patients randomized to one of the 2 optimal doses selected from the Phase 1 portion (with an acceptable safety profile seen in Phase 1). For Phase 1, the treatment eye will be the eye with worse visual acuity or the one chosen by the investigator, however, the treatment eye cannot have a visual acuity no better than 20/200. For Phase 2a, the treatment eye will be the eye with worse visual acuity, and cannot have a visual acuity better than 20/80. Approximately 30 patients will participate in the Phase 1 dose escalation portion, and 38 patients will be enrolled in the Phase 2a portion (19 patients receiving optimal dose level X from Phase 1 and 19 receiving optimal dose level Y from Phase 1). In the Phase 1 portion, treatment will be assigned 5 sequential cohorts, with 3 patients per cohort in each of the first 4 cohorts and 6 patients in the fifth cohort. Cohort A patients will be treated first, followed by Cohort B patients. All patients in a given cohort must have completed at least 4 weeks of post-treatment follow-up before patients in the next cohort may be treated. Follow-up will include postoperative follow-up period of 12 months (Day 2, Day 7, Day 15, Week 3, Week 4, Months 2, 3, 6, and 12) and long-term safety follow-up period (patients will be evaluated every 6 months for safety assessments). Safety assessments will include vital signs, AEs, and concomitant medications and routine 12-lead electrocardiograms (ECG). The anticipated study duration will be approximately 5 years (1 year in the 12-month postoperative follow-up period; up to 4 years in the long-term safety follow-up period).
Patients will be administered with XCHT (9 g, qd, po) for 5 days each cycle of irinotecan chemotherapy for 3 cycles. The XCHT administration begins 3 days before chemotherapy in each cycle, that is the chemotherapy begins on the 4th day of XCHT administration. Plasma will be collected for pharmacokinetic testing (using raloxifene 60mg po as probe), on the day before chemotherapy, that is on the 3rd day of XCHT administration in each cycle.
Japanese quails (Coturnix japonica) have a high reproductive rate because they reach sexual maturity very early. This short rearing time results in increasing interest among breeders and consumers. The aim of the study was a comparative analysis of two genotypes and sexes of Japanese and Pharaoh quails and their impact on body weight, carcass composition, meat quality, digestive system morphometry and leg bone dimensions. The study involved 40 birds (10 females and 10 males), Japanese quail and Pharaoh quail, 42 days old. Quail genotype had an effect (P < 0.05) on body weight, carcass weight, and some percentage of carcass elements. In addition, there was a significant effect of quail genotype on intramuscular fat and water content of pectoral and leg muscles. The origin of the quails interacted (P < 0.05) with the lightness (L*), yellowness (b*), cutting work, hardness, springiness, chewiness, gumminess, fibre cross-sectional area, vertical fibre diameter, and perimysium thickness of pectoral muscle. In addition, genotype was found to influence some anatomical traits, such as the percentage of proventriculus, heart, and liver on body weight, lengths and diameters of duodenum, caeca, and colon, and most dimensions of leg bones (femur and tibia). The sex of the birds significantly (P < 0.05) affected body weight, carcass weight, percentage of skin with subcutaneous fat in the carcass, as well as water content, lightness (L*), and springiness, most microstructure characteristics of pectoralis muscle, and also water and protein contents, and yellowness (b*) of leg muscles. In addition, differences were found between males and females (P < 0.05) in terms of duodenum and caeca diameter, length of greatest and medial femur, and greatest length of tibia. It can be stated that in terms of body weight and carcass weight as well as some meat quality features (protein content, fat content, fiber cross-sectional area), the pharaoh quail was the better genotype, while in terms of the proportion of muscles in the carcass and selected meat quality features: hardness, gumminess, chewiness, Japanese quails turned out to be better.
This is a single arm prospective study. All eligible subjects will receive neoadjuvant S-1 and concurrent radiation followed by surgical resection. Subjects may receive adjuvant chemotherapy after surgical resection at the clinical discretion of the medical oncologists.
PURPOSE: A composition for treating atopic dermatitis containing an active protein complex secreted from stem cells is provided to minimize an immunological problem, a safety problem, a pharmaceutical problem, and individual deviation. CONSTITUTION: A composition for treating atopic dermatitis contains a culture medium of mesenchymal stem cells derived from teeth or bone marrow, as an active ingredient. The mesenchymal stem cells have positive immunological property for CD90, CD105, CD44, and CD73. The mesenchymal stem cells grow by being adhered onto a cell culture dish and have a spindle-shape morphological property. The mesenchymal stem cells are differentiated to mesoderm. A method for manufacturing the composition comprises the steps of: culturing the mesenchymal stem cells in a conditioned medium; and collecting the culture medium. [Reference numerals] (AA) Induce atopic dermatitis : DNCB (2,4-dinitrochlorobenzene); (BB) Applying INF-γ-enhanced stem cell CM; (CC) Atopic dermatitis wound healing; (DD) Enhance IFN-γ; (EE) Increase the expression of a material which reduces autoimmunity-related factors; (FF) 1. Wound healing; (GG) 2. Reduce autoimmunity-related factors
BACKGROUND: Rauch-Steindl syndrome (RAUST) is a very rare genetic syndrome caused by a pathogenic variant in NSD2 on chromosome 4p16.3. Although NSD2 was previously thought to be the major gene in Wolf-Hirschhorn syndrome (WHS), a contiguous gene syndrome of chromosome 4p16.3 deletion, RAUST has been found to present different facial and clinical features from WHS. In this study, we report the details of two newly diagnosed individuals with RAUST in order to better understand the molecular and clinical features of RAUST.
METHODS: Whole-genome sequencing was performed on two individuals with psychomotor delay and growth failure. Detailed clinical evaluation of growth parameters, craniofacial features, electroencephalogram (EEG), magnetic resonance imaging of the brain, and developmental assessment were performed.
RESULTS: Both individuals had de novo truncating variants in NSD2. One had a novel variant (c.2470C>T, p.Arg824*), and the other had a recurrent variant (c.4028del, p.Pro1343Glnfs*49). Both exhibited characteristic RAUST facial features, growth failure, and mild psychomotor delay. A novel finding of RAUST was seen in individual 2, a Chiari malformation type 1, and both showed delayed bone age. They lacked common WHS features such as congenital heart defects, cleft lip/palate, and seizures (EEG with abnormal findings).
CONCLUSION: We present a novel variant and clinical presentations of RAUST, expand the molecular and clinical diversity of RAUST, and improve our understanding of this rare syndrome, which is distinct from WHS. Further researches are needed on more RAUST cases and on functional analysis of NSD2.
The study features activities that include development and refinement of a culturally-specific cognitive behavioral therapy that integrates aspects of drug abuse treatment with HIV medication adherence interventions and cultural elements of being a gay or bisexual man receiving medical care for HIV/AIDS. To estimate the size of the signal of this intervention, the study proposes a two parallel group design in which 50 treatment-seeking HIV-seropositive gay and bisexual men who meet criteria for methamphetamine abuse and who receive HIV medical care at the UCLA Center for Clinical AIDS Research and Education (CARE) clinic are randomized to the study condition or a treatment-as-usual (TAU) condition. Participants assigned to the experimental condition receive 12 weeks of twice-weekly GCBT, with a 6-months post-randomization follow-up visit. Participants assigned to the TAU condition are referred to the UCLA Addiction Medicine Clinic (AMC), where they receive the clinic's standard of care treatment for methamphetamine dependence for 12 weeks, and return for a 6-month follow-up visit. Analyses are conducted on all participants who meet inclusion/exclusion criteria, express desire for treatment, and receive at least one "dose" of the cognitive-behavioral treatment or make one visit to the AMC. Participants in both conditions agree to weekly and monthly data collection visits, including the provision of urine samples. Primary outcome variables are methamphetamine use, sexual risk behaviors, and HIV medication compliance. The proposed design maintains the focus on intervention development and feasibility, while recognizing that the second phase of this development will be informed by having accurate estimates of effect sizes for the intervention and adequate resources to conduct the full-scale trial.
The trial will recruit trainee anaesthetists of ST3 grade or higher who take part in a resident night-shift rota at Nottingham University Hospitals NHS Trust. Participants will undergo baseline psychometric testing to measure baseline mood. There will be a series of questions to ascertain levels of fatigue. All participants will then be asked to perform a standardised ultrasound-guided peripheral nerve blockade task using a high fidelity bench-top phantom model. Performance in this task will be independently assessed using a previously-validated scoring tool by two raters blinded to participant group allocation.
The present invention relates to a conjugate having tumor selectivity for targeted treatment, and more particularly, to a conjugate having tumor selectivity for targeted treatment characterized by the combination of the properties of a sound and light sensitizer, an angiogenesis inhibitor, and tyrosine kinase. The conjugate is characterized by the inclusion of a sound and light sensitizer, an angiogenesis inhibitor, tyrosine kinase, a target ligand, and a linker. According to the present invention, the conjugate having tumor selectivity for targeted treatment and the application thereof are more specific to photodynamic therapy, have the properties of an angiogenesis inhibitor and a tyrosine kinase inhibitor, and may be used for the production of medicine for the treatment of cancer and other diseases. In particular, the present invention relates to a method for preparing a drug and to a compound based on curcuminoids and porphyrin conjugates for the treatment of cancer and other diseases. Further, the present invention relates to a treatment method based on the composition, and the proposed drugs may provide anticancer, anti-angiogenesis, and inhibitory effects, as well as the advantageous effects of excellent solubility in an aqueous solution, bioavailability, stability, and non-toxicity. Moreover, the present invention may be administered orally, nasally, or rectally for the treatment of cancer and other diseases.
Part 1b will evaluate the PK profile and assess PDy data from blood and tumor tissue samples following TSR-033 treatment. The participants will begin treatment with TSR-033 on Day 1 followed by 28 days observation for collection of blood sampling for PK/PDy. Participants will receive their second dose of TSR-033 on Day 29 and every 14 days thereafter.
A ketamine infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
OBJECTIVE: Diets rich in live microbes can bring various health benefits. However, the association between dietary live microbe intake and frailty has not been studied.
METHODS: The study utilized data from the National Health and Nutrition Examination Survey (NHANES) 2007-2018. A total of 11,529 participants were included. Sanders et al. classified the level of live microbes in foods into low (<104 CFU/g), medium (104-107 CFU/g), or high (>107 CFU/g). With the methodology of Sanders et al. and dietary questionnaire data, participants were divided into three groups: (1) low dietary live microbe intake group (only low-level foods), (2) medium dietary live microbe intake group (medium but not high-level foods), and (3) high dietary live microbe intake group (any high-level foods). Additionally, foods with medium and high live microbe content were aggravated as MedHi. Frailty index ≥0.25 is defined as frailty. The weighted logistic regression analysis was conducted to examine the relationship between the intake of dietary live microbe and frailty. The restricted cubic splines (RCS) were employed to detect the nonlinear relationships.
RESULTS: In the fully adjusted model, participants with high dietary intake of live microbe had a significantly lower risk of frailty than those with low dietary intake of live microbe (OR = 0.67, 95% CI: 0.56, 0.79). For every 100 grams of MedHi food consumed, the risk of frailty decreased by 11% (OR = 0.89, 95% CI: 0.85, 0.92) after adjusting all covariates. The RCS indicated the existence of non-linear relationships. For those who consumed less than 100 grams of MedHi, increasing MedHi intake may significantly reduce the risk of frailty, but after exceeding 100 grams, the curve gradually levels off.
CONCLUSIONS: Our results suggested that increasing dietary live microbe intake was associated with a lower risk of frailty. However, more research is needed to verify this.
The response patterns of immune checkpoint inhibitors (ICIs) in solid tumors are diverse and complicated. Pseudoprogression, progression and even hyperprogression can occur. The main mechanism of pseudoprogression is the infiltration of immune cells into the tumor lesion, causing blurred tumor margins and even an increase in the volume of the entire tumor lesion (secondary delayed response). For pseudoprogression, irRC, irRECIST, iRECIST and other immune-related solid tumor efficacy evaluation criteria based on anatomical images are not enough to confirm, and the inflammation caused by T cell infiltration also shows strong uptake of 18F-FDG. The existing criteria for the response evaluation in solid tumors cannot early identify progression or pseudoprogression.

Fibroblast activation protein (FAP) is highly specifically expressed on the membrane surface of carcinoma-associated fibroblast (CAF). FAP-positive CAFs exist in a variety of solid tumors including rectal cancer and are mainly involved in the formation of tumor stroma. However, FAP is rarely expressed in normal tissues. Therefore, 68Ga-FAPI-04 PET, a FAP-targeted imaging modality, can be used to differentiate tumors and normal tissues and has been widely used in clinical studies. Its sensitivity and specificity outperformed 18F-FDG PET. Studies have shown that tumors with high FAP expression are associated with poor response immunotherapy. Although FAP-targeted imaging has been widely used in predicting the response to immune checkpoint inhibitors, it has rarely been reported in rectal cancer.

This study is a prospective monocentric study aimed to explore the value of 68Ga-FAPI-04 PET imaging in the early response evaluation of rectal cancer patients treated with immunotherapy. Patients with histopathologically confirmed diagnosis of rectal cancer will be recruited and undergo 68Ga-FAPI-04 and 18F-FDG PET imaging before treatment and after short-course radiotherapy and two cycles of neoadjuvant chemotherapy plus immunotherapy. The two imaging intervals will be completed two days apart. The efficacy of 68Ga-FAPI-04 in early response evaluation will be compared with the general imaging agent 18F-FDG.
The invention relates to a propolis-lycopene composition. The propolis-lycopene composition comprises: by weight, 2 to 6 parts of propolis, 0.8 to 7.5 parts of a lycopene raw material, 0.07 to 2.2 parts of vitamin E, and 0.075 to 0.5 parts of a selenium nutrient. The invention also relates to a propolis-lycopene composition preparation and especially relates to a propolis-lycopene composition soft capsule and a preparation method thereof. The propolis-lycopene composition is prepared from natural raw materials and has a scientific formula and controllable quality. The propolis-lycopene composition soft capsule has good stability and good disintegration effects. An animal experiment proves that the propolis-lycopene composition soft capsule has an effect of improving immunity and also has good safety.
Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.
Recent advances in fatty acid analysis have highlighted the links between lipid disruption and disease development. Lipid abnormalities are well-established risk factors for many of the most common chronic illnesses, and their involvement in asthma is also becoming clear. Here, we review research demonstrating the role of abnormal lipid metabolism in asthma, with a focus on saturated fatty acids and sphingolipids. High levels of palmitic acid, the most abundant saturated fatty acid in the human body, have been found in the airways of asthmatic patients with obesity, and were shown to worsen eosinophilic airway inflammation in asthma model mice on a high-fat diet. Aside from being a building block of longer-chain fatty acids, palmitic acid is also the starting point for de novo synthesis of ceramides, a class of sphingolipids. We outline the three main pathways for the synthesis of ceramides, which have been linked to the severity of asthma and act as precursors for the dynamic lipid mediator sphingosine 1-phosphate (S1P). S1P signaling is involved in allergen-induced eosinophilic inflammation, airway hyperresponsiveness, and immune-cell trafficking. A recent study of mice with mutations for the elongation of very long-chain fatty acid family member 6 (Elovl6), an enzyme that elongates fatty acid chains, has highlighted the potential role of palmitic acid composition, and thus lipid balance, in the pathophysiology of allergic airway inflammation. Elovl6 may be a potential therapeutic target in severe asthma.
The concept of schizophrenia as a mental condition is subject to deconstruction for a broader approach toward a systemic disorder by encompassing the links with inflammation. Beyond the salient psychotic symptoms of schizophrenia, the negative symptoms remain the silent cause of deterioration and the hallmark of a worse prognosis. Either as part of a unitary disorder or as a distinct subtype of schizophrenia, the negative symptoms seem to be associated with specific biological features. They might suggest a more transparent phenotype of the underlying pathological process. Therefore, recent lines of research indicate that peripheral immune alterations may be predictive early-phase biomarkers for targeting a specific subgroup of schizophrenia patients at risk of later developing enduring negative symptoms. In this paper, we review 1. The most influential theories of inflammation in schizophrenia, in conjunction with 2. The hitherto data linking immune alterations to negative symptoms. Thus, we propose a theoretical framework to delineate a model of inflammatory endophenotype for the negative symptoms of schizophrenia.